Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Foliglurax (PXT002331) for reducing levodopa-induced dyskinesia and wearing-off in Parkinson's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Foliglurax (foliglurax)

Snippet

Sponsor: Prexton Therapeutics | Conditions: Parkinson Disease | Phase 2 | Status: WITHDRAWN